Generic placeholder image

Cardiovascular & Hematological Disorders-Drug Targets


ISSN (Print): 1871-529X
ISSN (Online): 2212-4063

Review Article

Adenosine as a Marker and Mediator of Cardiovascular Homeostasis: A Translational Perspective

Author(s): Trevor Simard, Richard Jung, Alisha Labinaz, Mohammad Ali Faraz, F. Daniel Ramirez, Pietro Di Santo, Ian Pitcher, Pouya Motazedian, Chantal Gaudet, Rebecca Rochman, Jeffrey Marbach, Paul Boland, Kiran Sarathy, Saleh Alghofaili, Juan J. Russo, Etienne Couture, Rob S. Beanlands and Benjamin Hibbert*

Volume 19 , Issue 2 , 2019

Page: [109 - 131] Pages: 23

DOI: 10.2174/1871529X18666181011103719

Price: $58


Adenosine, a purine nucleoside, is produced broadly and implicated in the homeostasis of many cells and tissues. It signals predominantly via 4 purinergic adenosine receptors (ADORs) – ADORA1, ADORA2A, ADORA2B and ADORA3 in addition to non-ADOR mediated effects. Through these signaling mechanisms, adenosine exerts effects on numerous cell types crucial to maintaining vascular homeostasis, especially following vascular injury. Both in vitro and in vivo models have provided considerable insights into adenosine signaling and identified targets for therapeutic intervention. Numerous pharmacologic agents have been developed that modulate adenosine signaling, both through design as specific ADOR agonists and antagonists and as offtarget effects of existing anti-platelet medications. Despite this, adenosine has yet to be firmly established as either a therapeutic or a prognostic tool in clinical medicine to date. Herein, we provide a bench-to-bedside review of adenosine biology, highlighting the key considerations for further translational development of this promising molecule.

Keywords: Adenosine, cardiovascular, translational, pre-clinical, restenosis, biomarker.

Graphical Abstract

Rights & Permissions Print Export Cite as
Article Metrics
Related Journals
Related eBooks